Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis
- 1Wits Advanced Drug Delivery Platform Research Unit Department of Pharmacy and Pharmacology School of Therapeutic Sciences Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa wits.ac.za
- 2Infectious Diseases and Oncology Research Institute (IDORI) Faculty of Health Sciences University of the Witwatersrand Johannesburg South Africa wits.ac.za
Abstract
Tuberculosis was a lethal disease until the early 1950s, when the first anti‐TB drugs were discovered. These drugs saved many lives until bacteria developed resistance in the 1980s. As a result, TB has re‐emerged as a global health challenge, affecting both drug‐susceptible and drug‐resistant cases. Although tuberculosis is a preventable and curable disease, it remains a major global health burden for both adults and children. High‐prevalence cases in children threaten eradication efforts because they can become fatal in the future. The review is aimed at compiling knowledge on pediatric TB treatment, particularly oral formulations. Efforts have been made over the years to improve pediatric TB treatment. Challenges remain in gathering pharmacokinetic data for children, distributing child‐friendly formulations worldwide, and strengthening collaboration among stakeholders. These issues affect clinical outcomes and hinder the eradication of this infection. Currently, there is a global initiative to improve access to high‐quality TB medications and to utilize new technology, such as developing nanoformulations and dispersible tablets, for better drug delivery. Continued progress, innovation, and fostering partnerships are necessary to overcome existing challenges in TB treatment and to develop child‐friendly formulations.
Related
- Anterior Chest Wall Tuberculosis Masquerading as a Chronic Parasternal Sinus in an Apparently Immunocompetent Adult: A Diagnostic Challenge in a Resource-Limited Setting.
- Assessing the current landscape of North American pediatric nutrition support teams: A survey study
- Tuberculosis of the Sphenoid Sinus Causing Blindness in a Pediatric Patient: A Case Report.
- High Initiation but Suboptimal Completion of Tuberculosis-Preventive Treatment Among People Living With HIV on Antiretroviral Therapy, Persistent Tuberculosis Incidence, and Programmatic Implications: Findings From a 2-Year Multicountry Cohort Study
- Determinants of willingness to accept Tuberculosis Preventive Treatment (TPT) among close contacts with Tuberculosis Infection (TBI) in Xinjiang, China
BibTeX
@article{dumeni2026tiny,
title = {{Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis}},
author = {Lucia N. Dumeni and Pradeep Kumar and Yahya E. Choonara},
journal = {Pulmonary Medicine},
year = {2026},
month = oct,
doi = {10.1155/pm/9686798},
url = {https://doi.org/10.1155/pm/9686798},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis
AU - Lucia N. Dumeni
AU - Pradeep Kumar
AU - Yahya E. Choonara
PY - 2026
DA - 2026/10/28
JO - Pulmonary Medicine
DO - 10.1155/pm/9686798
UR - https://doi.org/10.1155/pm/9686798
AB - Tuberculosis was a lethal disease until the early 1950s, when the first anti‐TB drugs were discovered. These drugs saved many lives until bacteria developed resistance in the 1980s. As a result, TB has re‐emerged as a global health challenge, affecting both drug‐susceptible and drug‐resistant cases. Although tuberculosis is a preventable and curable disease, it remains a major global health burden for both adults and children. High‐prevalence cases in children threaten eradication efforts because they can become fatal in the future. The review is aimed at compiling knowledge on pediatric TB treatment, particularly oral formulations. Efforts have been made over the years to improve pediatric TB treatment. Challenges remain in gathering pharmacokinetic data for children, distributing child‐friendly formulations worldwide, and strengthening collaboration among stakeholders. These issues affect clinical outcomes and hinder the eradication of this infection. Currently, there is a global initiative to improve access to high‐quality TB medications and to utilize new technology, such as developing nanoformulations and dispersible tablets, for better drug delivery. Continued progress, innovation, and fostering partnerships are necessary to overcome existing challenges in TB treatment and to develop child‐friendly formulations.
SN - 2090-1836
SN - 2090-1844
ER -